Market Place
Sourcing Support
Evommune Presents Positive EVO756 Data At GA²LEN Urticaria Forum
04 Dec 2024 //
PR NEWSWIRE
Evommune Begins Phase 2 Trial of EVO756 in Chronic Inducible Urticaria
03 Sep 2024 //
PR NEWSWIRE
Evommune Reports Positive POC Trial For MRGPRX2 Antagonist EVO756
16 Jul 2024 //
PR NEWSWIRE
Evommune Inks License Agreement with AprilBio for Biologics and Antibody Drugs
26 Jun 2024 //
PHARMABIZ
Evommune Secures Rights to Commercialize IL-18 Fusion Protein From AprilBio
24 Jun 2024 //
PR NEWSWIRE
Evommune Announces Initiation of a Phase 1 Trial of its MRGPRX2 Antagonist
18 Jan 2024 //
PR NEWSWIRE
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
28 Nov 2023 //
PR NEWSWIRE
Evommune Announces Strategic Collaboration with Maruho to Develop MRGPRX2
27 Sep 2023 //
PR NEWSWIRE
Evommune drops IRAK4 inhibitor on phase 2 dermatitis data
27 Sep 2023 //
FIERCE BIOTECH
Evommune Adds Additional Investment In Series B Financing
28 Jun 2023 //
PR NEWSWIRE
Evommune Initiates Phase 2a Trial to Evaluate EVO101 in Atopic Dermatitis
28 Sep 2022 //
PRNEWSWIRE
Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101
21 Mar 2022 //
PRNEWSWIRE
Evommune Completes $83 Million Series A Financing
10 Sep 2021 //
TRIALSITENEWS
Evommune snags $83M for "Tylenol for itch," three other programs
09 Sep 2021 //
FIERCEBIOTECH
The old Dermira team heads for clinic; takes candidates back from Eli Lilly,
09 Sep 2021 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.